* If you want to update the article please login/register
At a 6-month follow-up, the aim is to assess the safety and effectiveness of valsartan/sacubitril against enalapril in patients with acute heart failure. Methods In this prospective, single center, and observational research, published in India between September 2017 and February 2020, patients with acute decompensated heart disease (without reduced ejection fractions were included in this prospective, single center, and observational study. In the ACEI group, the mean maximum tolerated dose by population in the ARNI group was 203. 6 mg and 8. 9 mg. Readmission for heart failure was seen much higher in the ACEI group than in the ARNI group. Ejection fraction, left ventricular end diastolic, and systolic measurements, 6 min walk test, and Kansas City Cardiomyopathy Questionnaires revealed p values 0. 05 between the groups. Conclusions The ARNI research group achieved improved safety and efficacy outcomes at the end of the 6 month follow-up period relative to the ACEI group.
Source link: https://europepmc.org/article/MED/35483448
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions